Overview
In patients with malignancies, contrast-enhanced abdominal CT (hereafter abdominal CT) plays an important role in detecting carcinoma recurrence and assessing treatment response. In this study, we aim to investigate whether such a "double low" dose CT is feasible in patients with liver metastases of colorectal cancer using a vendor-agnostic artificial intelligence-based noise reduction and contrast enhancement software.
Eligibility
Inclusion Criteria:
- colorectal cancer (CRC) patients
- on surveillance or monitoring for liver metastasis (of CRC)
Exclusion Criteria:
- any relative or absolute contra-indication of CECT
- diffuse infiltrative type of liver metastasis or on monitoring for too many liver lesions